Ana Callejo

Burgos, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.

Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.

Journal: Genome medicine

Published: November 07, 2025

Revisiting Alma Ata: A Blueprint for Cancer Care.

Revisiting Alma Ata: A Blueprint for Cancer Care.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: July 30, 2025

Oncology with common sense: beyond biologistic and pharmacological models.

Oncology with common sense: beyond biologistic and pharmacological models.

Journal: Ecancermedicalscience

Published: June 15, 2025

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 06, 2024

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 05, 2024

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study.

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study.

Journal: Frontiers in oncology

Published: October 12, 2024

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 07, 2024

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.

Journal: Cancers

Published: November 17, 2023

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.

Journal: Cancers

Published: March 15, 2023

Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.

Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.

Journal: Molecular oncology

Published: December 16, 2022

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 21, 2022

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.

Journal: Journal for immunotherapy of cancer

Published: February 24, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026